Diamyd Medical's President and CEO comments in the company's interim report
today on several significant advances during the period, including the positive
development of the company's Phase III program.
“I'm very pleased with how the operations has developed this quarter,” says
Elisabeth Lindner, President and CEO of Diamyd Medical. “Patient recruitment for
the European Phase III study is very successful. Now when we have also received
approval to include children from age 10 in the US, we can further accelerate
the recruitment," Lindner continues.
Diamyd Medical announced during the third quarter that more than half of the
patients had been included in the European Phase III study. After the end of the
period, the FDA has approved the inclusion of children from age 10 in the US
study. The company can now contract more pediatric clinics and further
accelerate patient recruitment.
During the period, Diamyd Medical also reported that the Swedish Medical
Products Agency approved a Phase II study of the Diamyd® vaccine with the
objective to prevent or delay the development of type 1 diabetes in children at
high risk of developing the disease.
For additional information, please contact:
Elisabeth Lindner, President and
CEO, Diamyd Medical AB (publ.)
Tel: +46 (0)8 661 0026
For pictures and press
material, please contact:
Alexandra Fleetwood, Director Communications, Diamyd
Medical AB (publ.), alexandra.fleetwood@diamyd.com
Tel: +46 (0)8 661 0026
About Diamyd Medical
Diamyd Medical is a Swedish diabetes company focusing on
the development of pharmaceuticals for the treatment of autoimmune diabetes and
its complications. The company's most advanced project is the GAD-based drug
Diamyd® for type 1 diabetes. Phase III trials for this drug are in progress in
both Europe and the US. In addition, the company has initiated clinical studies
in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery
System (NTDDS). The company has also out-licensed the use of GAD for the
treatment of Parkinson's disease. The company currently has three clinical-phase
products.
Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq
OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY)
administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).
Further information is available on the company's website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the requirements
stated in the listing agreements.
Diamyd Medical AB (publ.)
Linnégatan 89 B,
SE-115 23 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46 (0)8 661 63 68
E-mail: info@diamyd.com. VAT no: SE556530-142001.
(www.omxnordicexchange.com
ticker: DIAM B; www.otcqx.com ticker: DMYDY)
